Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

EP: 1.The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

EP: 2.An Overview of Adalimumab Biosimilars

EP: 3.The Pharmacological Aspects of Adalimumab Biosimilars

EP: 4.The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases

EP: 5.Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings

EP: 6.The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars

Now Viewing

EP: 7.Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

EP: 8.Selecting Between Adalimumab Biosimilars for Your Patients

EP: 9.Switching From Adalimumab to a Biosimilar

EP: 10.Clinical Experience With Initiating Adalimumab Biosimilars

This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The conversation explores strategies to enhance the uptake of biosimilars, focusing on easing administrative burdens and improving patient access and affordability. Locally, initiatives have been implemented to streamline processes, such as eliminating prior authorizations for renewals of certain medications like adalimumab and reducing copayments for patients. These measures have positively impacted biosimilar uptake in the area.

Strategies for improving uptake include ensuring cost savings for patients, expanding formulary coverage to include more interchangeable products, and enhancing patient education. Patient support programs, including co-pay assistance cards and reimbursement specialists, play a crucial role in promoting biosimilar adoption, especially among Medicare and Medicaid patients. Access to these programs influences treatment decisions alongside considerations of safety and efficacy.

The conversation underscores the importance of balancing cost-saving measures with patient affordability and accessibility. It highlights the complexities clinicians face when navigating the healthcare landscape, where expensive branded medications may be accessible due to support programs, while cheaper alternatives like biosimilars remain out of reach for some patients. Ultimately, addressing these challenges requires a multifaceted approach that considers both systemic cost-saving measures and individual patient affordability.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.